October 29, 2014
To whom it may concern:
Company Name
RepresentativeContact :TOHO HOLDINGS CO., LTD
Norio Hamada /President and Representative Director(Securities Code: 8129 / First Section ofTokyo Stock Exchange)
Katsuya Kato, Director andGeneral Manager of Corporate
Communications Officeand Corporate Planning Office(TEL: 03-6838-2803)

Notice Regarding Business Alliance and Share Acquisition
with Kokando and Kyoso Mirai Asia Pte.Ltd
TOHO HOLDINGS CO., LTD.(“TOHO HOLDINGS” hereinafter) hereby announces that it has agreed today tohave business alliance with Kokando and Kyoso Mirai Asia Pte.Ltd（“Kokando and Kyoso Mirai Asia” hereinafter,
Head office: Singapore, President: Mitsutaka Iida）, which is established by KOKANDO Co., Ltd.（“KOKANDO”
hereinafter, Head office: Toyama City, Toyama, CEO: Yasuhiko Shioi）concerning the produce and sale of medicaland healthcare goods in Southeast Asia and to acquire some part of shares of Kokando and Kyoso Mirai Asia.
Today, TOHO HOLDINGS concluded a basic agreement at the Embassy of Japan in Singapore.

1. Background and purpose for the capital and business alliance
TOHO HOLDINGS, the group slogan “Total Commitment to Good Health”, developed and provided varioussystems and services under the mission not only to distribute pharmaceuticals but also to improve medical services
and support self-medication. Furthermore, TOHO HOLDINGS strived to expand the networks which are as thecore of pharmaceutical wholesaling and dispensing pharmacy based on the philosophy “Kyoso Mirai” in order tocreate the distribution value utilized the basis of pharmaceutical wholesaling.
As for overseas business development, in addition to wholesaling business in China, TOHO HOLDINGS aims asa strategic policy of “Medium-term Management Plan14-16” to promote personnel exchanges between partnerships
in the United States and Southeast Asia and to reinforce the approaches such as investigations and researches topharmaceutical distributions in foreign countries and business development in the healthcare market.
On the other hand, KOKANDO will supervise the local subsidiaries which sell medical-related products in thefive countries of Southeast Asia by the establishment of Kokando and Kyoso Mirai Asia and arrange the salestructure like sales network expansion, substantial line-ups and construction of distributing management systems
towards enhancement of competitiveness in that fast-growing area. Also, KOKANDO attempts to make crude drug
products which are Japanese traditional drugs become familiar.
Both Companies expect to complement each other in fields of production, import and export, sale, anddistributing management know-how concerning medical devices, medical materials and healthcare-related goods.
Besides, by constructing hub function to promote pharmaceutical-related business in Southeast Asia, we suppose to
be able to contribute to the expansion of our networks of Kyoso Mirai.

2. Outline of Kokando and Kyoso Mirai Asia Pte.Ltd
Company Name

Kokando and Kyoso Mirai Asia Pte.LtdPrincipal place

10 Anson Road #18-10 International Plaza Singapore

Corporate representative

Mitsutaka Iida / President

Business contents①Production of drugs, quasi-drugs, medical devices, cosmetics and softdrinks②Wholesale of drugs, quasi-drugs, medical devices, cosmetics, convenience
goods, food for health use and food
③Import and export of things stated above④Management of retailing like drug stores⑤Development and sale of systems for medical institutions⑥Investigation on medication and producing and distributing drugs, offering
information and consulting

Business area

Singapore, Thailand, Malaysia, Hong Kong, Korea

Establishment

January 1, 2015

Fiscal year end

December 31

3. Schedule
Conclusion of the basic agreement：

October 29, 2014

Conclusion of agreement on the stock transfer： Late January, 2015
Stock transfer date：

Late February, 2015 (planned)

4. Impact of the Share Acquisition
There will be little influence on its consolidated financial results in FY2015.